Compile Data Set for Download or QSAR
Report error Found 28 Enz. Inhib. hit(s) with all data for entry = 12987
TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477131BDBM477131(US10888567, Compound 42 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477136BDBM477136(US10888567, Compound 47 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477156BDBM477156(US10888567, Compound 66 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477107BDBM477107(US10888567, Compound 3 | US11414428, Compound 1 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477158BDBM477158(US10888567, Compound 67 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477138BDBM477138(US10888567, Compound 49 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477122BDBM477122(US10888567, Compound 16 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477116BDBM477116(US10888567, Compound 11 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 565432BDBM565432(US11414428, Compound 17 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477105BDBM477105(US10888567, Compound 1 | US20250186410, Compound 1)
Affinity DataIC50: 5.50E+3nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477110BDBM477110(US10888567, Compound 5 | US20250186410, Compound 5)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477183BDBM477183(US10888567, Compound 89 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477109BDBM477109(US10888567, Compound 4 | US20250186410, Compound 4)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477178BDBM477178(US10888567, Compound 84 | US20250186410, Compound ...)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477113BDBM477113(US10888567, Compound 8 | US20250186410, Compound 8)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477111BDBM477111(US10888567, Compound 6 | US20250186410, Compound 6)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477114BDBM477114(US10888567, Compound 9 | US20250186410, Compound 9)
Affinity DataIC50: 5.50E+4nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477189BDBM477189(US10888567, Compound 95 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477133BDBM477133(US10888567, Compound 44 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477134BDBM477134(US10888567, Compound 45 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 748301BDBM748301(US20250186410, Compound 41)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477166BDBM477166(US10888567, Compound 74 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477121BDBM477121(US10888567, Compound 15 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477120BDBM477120(US10888567, Compound 14 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477117BDBM477117(US10888567, Compound 12 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 477115BDBM477115(US10888567, Compound 10 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 565430BDBM565430(US11414428, Compound 15 | US20250186410, Compound ...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Antido Therapeutics International

US Patent
LigandChemical structure of BindingDB Monomer ID 8304BDBM8304(5-phenylpyrido[3,2-d][1,2]oxazol-3-amine | isoxazo...)
Affinity DataIC50: 1.00E+5nMAssay Description:Recombinant human IDO1 (rhIDO1) was expressed and purified from cultures of EC538 strain of E. coli transformed with pREP4 and pQE9-IDO plasmid. Reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent